This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (148)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JAMES A. WHITESIDE, M.D.; FRED S. PHILIPS, M. D.; HAROLD W. DARGEON, M.D.; JOSEPH H. BURCHENAL, M.D.

AMA Arch Intern Med. 1958;101(2):279-285.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The difficulty in managing acute leukemia in children is enhanced by the occurrence of neurological manifestations. It is especially true when this component of the disease occurs, as it may, during a period with few positive physical findings and a bone marrow in remission. Prior to the use of current chemotherapeutic agents, leukemic-cell invasion of the parenchyma of the brain, meninges, and cranial nerves was noted frequently at postmortem examination.^1,2 At times this involvement was closely correlated with clinical symptoms which presented early in the course of the disease. At present the leukemic child who develops central nervous system manifestations often does so while being given maintenance antileukemic therapy months after the initial diagnosis is made. This suggests that these current agents are only partially effective against the leukemic cell in the central nervous system in the conventional dosage and route of administration. To supplement the incomplete response of . . . [Full Text PDF of this Article]

Author Affiliations
New York

From the Pediatric and Chemotherapy Services of Memorial Center for Cancer and Allied Diseases; the Divisions of Experimental and Clinical Chemotherapy, Sloan-Kettering Institute for Cancer Research, and the Department of Medicine, Cornell University Medical College.

Footnotes
Submitted for publication Sept. 30, 1957.

Present address of Dr. Whiteside: Department of Pediatrics, University of Miami School of Medicine, Miami, Fla.

These studies were supported by research grants C1889 and CY3215 from the National Cancer Institute of the National Institutes of Health, Public Health Service; institutional grants from the American Cancer Society; the Damon Runyon Memorial Fund for Cancer Research; Lasker Foundation; Grant Foundation; Black-Stevenson Fund, and the Children's Tumor Registry.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?